

Basic science (July 2005)

1. Altundag K, Altundag O, Morandi P, Ozcakar B, Boruban C. The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. *Mol Cancer Ther* 2005; **4**: 1136.
2. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. *J Clin Oncol* 2005; **23**: 4687–4694.
3. Barry JB, Giguere V. Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha. *Cancer Res* 2005; **65**: 6120–6129.
4. Begon DY, Delacroix L, Vernimmen D, Jackers P, Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. *J Biol Chem* 2005; **280**: 24428–24434.
5. Boulay A, Rudloff J, Ye JJ, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen SU, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling *in vitro* induces cell death in models of breast cancer. *Clin Cancer Res* 2005; **11**: 5319–5328.
6. Buhler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy *in vitro* and *in vivo*. *Mol Cancer Res* 2005; **3**: 365–371.
7. Butt AJ, Dickson KA, Jambazov S, Baxter RC. Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. *Endocrinology* 2005; **146**: 3113–3122.
8. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, Casavola V, Zaccolo M, Reshkin SJ. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. *Mol Biol Cell* 2005; **16**: 3117–3127.
9. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoutte J, Shao WL, Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. *Cell* 2005; **122**: 33–43.
10. Chen L, Madura F. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. *Cancer Res* 2005; **65**: 5599–5606.
11. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. *Oncogene* 2005; **24**: 5053–5068.
12. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancellato G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *Clin Cancer Res* 2005; **11**: 4741–4748.
13. De Servi B, Hermani A, Medunjanin S, Mayer D. Impact of PKC delta on estrogen receptor localization and activity in breast cancer cells. *Oncogene* 2005; **24**: 4946–4955.
14. Emberley ED, Niu YL, Curtis L, Troup S, Mandal SK, Myers JN, Gibson SB, Murphy LC, Watson PH. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. *Cancer Res* 2005; **65**: 5696–5702.
15. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, MacGrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. *Oncogene* 2005; **24**: 4660–4671.

Received: 19/09/05
Accepted: 19/09/05
First published online 03/01/06
BCO/499/2005/JW

16. Felty Q, Singh KP, Roy D. Estrogen-induced G(1)/S transition of G(0)-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. *Oncogene* 2005; **24**: 4883–4893.
17. Goodison S, Yuan G, Sloan D, Kim R, Li C, Popescu NC, Urquidi V. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. *Cancer Res* 2005; **65**: 6042–6053.
18. Gupta R, Sharma S, Sommers JA, Jin Z, Cantor SB, Brosh RM. Analysis of the DNA substrate specificity of the human BACH1 helicase associated with breast cancer. *J Biol Chem* 2005; **280**: 25450–25460.
19. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. *Mol Endocrinol* 2005; **19**: 1765–1778.
20. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW. Benign breast disease and the risk of breast cancer. *New Engl J Med* 2005; **353**: 229–237.
21. Henke BR, Heyer D. Recent advances in estrogen receptor modulators. *Curr Opin Drug Di Dev* 2005; **8**: 437–448.
22. Kelly T, Suva LJ, Huang Y, MacLeod V, Miao HQ, Walker RC, Sanderson RD. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. *Cancer Res* 2005; **65**: 5778–5784.
23. Kluger HM, Lev DC, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, Rimm DL, Price JE. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. *Cancer Res* 2005; **65**: 5578–5587.
24. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP, Weinberg RA, Rosenblatt M. A mouse mode of human breast cancer metastasis to human bone. *Cancer Res* 2005; **65**: 6130–6138.
25. Laganier J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V. From the Cover: Location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. *Proc Natl Acad Sci USA* 2005; **102**: 11651–11656.
26. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vjiver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JGM, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF and the Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. *Clin Cancer Res* 2005; **11**: 5175–5180.
27. Langsenlehner U, Hofmann G, Samonigg H, Krippel P, Renner W, Clar H. Cyclin D1 genotype and breast cancer metastasis. *Cancer Epidem Biomar Pre* 2005; **14**: 1844–1845.
28. Lewandowski SA, Thiery J, Jalil A, Leclercq G, Szczylik C, Chouaib S. Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity. *Oncogene* 2005; **24**: 4789–4798.
29. Li Q, Wu LY, Oelschlagel DK, Wan M, Stockard CR, Grizzle WE, Wang N, Chen HQ, Sun Y, Cao X. Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells. *J Biol Chem* 2005; **280**: 27022–27028.
30. Liu ZJ, Lee WJ, Zhu BT. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17 beta-hydroxysteroid dehydrogenase as the underlying cause. *Cancer Res* 2005; **65**: 5802–5811.
31. Loi S, Milne RL, Friedlander ML, McCredie MRE, Giles GG, Hopper JL, Phillips KA. Obesity and outcomes in premenopausal and postmenopausal breast cancer. *Cancer Epidem Biomar Pre* 2005; **14**: 1686–1691.
32. Mao X, Hamoudi RA, Zhao P, Baudis M. Genetic losses in breast cancer: toward an integrated molecular cytogenetic map. *Cancer Genet Cytogen* 2005; **160**: 141–151.
33. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. *Clin Cancer Res* 2005; **11**: 5188–5194.
34. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu WP, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. *Nature* 2005; **436**: 518–524.
35. Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, Thiele C, Lindeman GJ, Visvader JE, Pomorski T. StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. *J Biol Chem* 2005; **280**: 27436–27442.

36. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and *in vitro* propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. *Cancer Res* 2005; **65**: 5506–5511.
37. Ryden L, Jirstrom K, Bendahl PA, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. *J Clin Oncol* 2005; **23**: 4695–4704.
38. Schairer C, Hill D, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, Sherman ME. Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. *Cancer Epidem Biomar Pre* 2005; **14**: 1660–1665.
39. Sharma D, Blum J, Yang XW, Beaulieu N, Macleod AR, Davidson NE. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. *Mol Endocrinol* 2005; **19**: 1740–1751.
40. Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. *Oncogene* 2005; **24**: 4609–4623.
41. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, von Smitten K, Aittomaki K, Heikkila P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 pro72 homozygous genotype have a poorer survival. *Clin Cancer Res* 2005; **11**: 5098–5103.
42. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JMS. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? *Clin Cancer Res* 2005; **11**: 4835–4842.
43. Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ. Anti sense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. *Cancer Res* 2005; **65**: 6139–6150.
44. Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE, Hoon DSB. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. *Oncogene* 2005; **24**: 4721–4727.
45. Venter DJ, Ramus SJ, Hammet FMA, de Silva M, Hutchins AM, Petrovic V, Price G, Armes JE. Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. *Cancer Genet Cytogen* 2005; **160**: 134–140.
46. Yang CF, Liu Y, Leskow FC, Weaver VM, Kazanietz MG. Rac-GAP-dependent inhibition of breast cancer cell proliferation by beta 2-chimerin. *J Biol Chem* 2005; **280**: 24363–24370.
47. Zhang XT, Krutchinsky A, Fukuda A, Chen W, Yamamura S, Chalt BT, Roeder RG. MED1/TRAP220 exists predominantly in a TRAP/mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. *Mol Cell* 2005; **19**: 89–100.

Prepared by
R. Sutherland, J. Scorer
Cancer Research Program
Garvan Institute of Medical Research
Darlinghurst, NSW, Australia